CelLBxHealth (AGL) Investor Update summary

Strategic direction and business model

• New leadership is implementing a focused commercialization strategy, shifting from academic collaborations to strategic partnerships and lab service providers, especially in the U.S. oncology diagnostics market.

• The Parsortix platform is positioned as a best-in-class solution for circulating tumor cell (CTC) isolation, with strong clinical validation and integration into existing lab workflows.

• Key partnerships include Myriad Genetics and Roche, targeting unmet needs where tissue and ctDNA tests fail, and aiming to expand into high-throughput clinical environments.

• The company is narrowing its focus to work with select CROs and clinical labs, avoiding broad risk-sharing in drug development and emphasizing revenue-generating activities.

• A razor-blade model is being adopted, with consumables and technology transfers to U.S. labs, and a clear sales pipeline of £12.6 million gross, weighted to £4.5 million in expected revenues over two years.

Financial restructuring and operational changes

• A significant restructuring is underway, reducing headcount from 108 to 44 and consolidating facilities to cut costs and focus on commercial execution.

• Cash burn is targeted to decrease from £12.7 million to £5.5 million by 2026, with manufacturing outsourced to increase margins above 70%.

• Recent fundraising secured £6.8 million, with a retail offer of up to £1 million, providing a cash runway to execute the new plan.

• The company expects to reach break-even by the end of 2028, based on revenue growth to $8 million and strict cost controls.

• Staff reactions to cuts have been mixed, but those remaining are positive about the new direction and business plan.

Market opportunity and partnerships

• The liquid biopsy market is growing at 12% annually, with increasing recognition of the limitations of ctDNA and the need for CTC-based diagnostics.

• Strategic partnerships with major industry players are expected to drive adoption and revenue, with value inflection points anticipated in the next 12-18 months.

• The company is well-positioned for potential M&A activity, either as an acquirer or a target, as the market for CTC solutions expands.

• Ongoing collaborations with AstraZeneca and others are progressing, with a focus on clinical utility and integration into drug development and patient care.

• The company will move to quarterly reporting and focus communications on key milestones and partnership developments.